Mesoblast News

News

0

Ticker

MSB.AX

ISIN

AU000000MSB8

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Mesoblast Eulerpool News

6/25/2026, 8:41:20 AM

Regenerative Medizin: Europas Antwort auf die Herausforderungen chronischer Schmerzen

Regenerative Medicine: Europe's Response to the Challenges of Chronic Pain

12/19/2024, 4:59:36 PM

FDA erteilt grünes Licht für Mesoblasts Ryoncil: Revolution in der Behandlung von SR-aGvHD

FDA Gives Green Light to Mesoblast's Ryoncil: Revolution in the Treatment of SR-aGvHD

12/19/2024, 1:32:04 PM

Mesoblast feiert Durchbruch: FDA genehmigt Ryoncil als erste MSC-Therapie in den USA

Mesoblast celebrates breakthrough: FDA approves Ryoncil as the first MSC therapy in the USA

Mesoblast Stock News

Mesoblast is being monitored by journalists and investors worldwide. We gather the latest Mesoblast news here.

February 27·
Benzinga
Mesoblast shares are trading lower after the company reported worse-than-expected Q4 sales results.
February 27·
Benzinga
Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate
February 27·
SeekingAlpha
Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
February 26·
Benzinga
Earnings Scheduled For February 26, 2026
February 25·
Benzinga
What's Next: Mesoblast's Earnings Preview
February 20·
Yahoo
Mesoblast Financial Results and Corporate Update Webcast
February 12·
Benzinga
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy
February 12·
Benzinga
Reported Earlier, Mesoblast Data Shows 15% Early Mortality In Third-Line Ryoncil Treatment Versus 2% In Second-Line Phase 3 Trial Emphasizing Earlier Use Importance
February 12·
Yahoo
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
February 11·
SeekingAlpha
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
February 5·
Yahoo
ASX Growth Companies With High Insider Stakes To Watch
January 29·
Yahoo
Ryoncil® Net Revenues Increase for the Quarter to US$30M
January 27·
Benzinga
Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication
January 27·
Benzinga
Reported Earlier, Mesoblast's Ryoncil Demonstrates 84% Survival In Children With SR-aGvHD Following Completion Of FDA-Approved 28-Day Treatment
January 27·
Yahoo
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
January 25·
Yahoo
ASX Penny Stocks To Watch In January 2026
January 20·
Benzinga
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
January 20·
Benzinga
Reported Sunday, Mesoblast Announces FDA Acknowledgement Of Rexlemestrocel-L Pain Reduction Supporting 12-Month Efficacy In Chronic Low Back Pain
January 19·
Yahoo
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
January 9·
Yahoo
Markets in a Minute: Mesoblast, Alkane Resources shine

Mesoblast Stock Press Releases

Mesoblast regularly publishes news on the company's website that are relevant for investors.

February 24•
Mesoblast
Mesoblast Qtrly Loss Attributable $26 Mln
February 24•
Mesoblast
Mesoblast Reports Q2 Revenue Of $2.4 Million
January 24•
Mesoblast
Mesoblast Ltd Files Prospectus Relates To Offer And Sale From Time To Time By Oaktree Shareholders Of Up To 8.8 Million Co's Ordinary Share
November 24•
Mesoblast
Mesoblast Ltd Says Qtrly Loss Attributable $22.6 Mln
August 31•
Mesoblast
Mesoblast FY Loss Attributable $98.8 Million
August 9•
Mesoblast
Mesoblast Says CFO Josh Muntner To Leave
July 19•
Mesoblast
Mesoblast Says COVID ARDS Trial 90-Day Survival Outcomes Presented At ISCT
June 3•
Mesoblast
Mesoblast QTRLY Loss Attributable US$26.5 Mln
April 7•
Mesoblast
Mesoblast Ltd Files For Shelf Of Up To $180 Mln ADS Representing Ordinary Shares
March 2•
Mesoblast
Mesoblast Says Raised US$110 Mln Led By U.S. Strategic Investor Group
February 26•
Mesoblast
Mesoblast Ltd Posts HY Loss Attributable Of $50.2 Million
February 11•
Mesoblast
Mesoblast Updates On Phase 3 Trial Of Allogeneic MPC Therapy Results
December 18•
Mesoblast
Mesoblast Updates On Covid-19 Ards Trial
December 14•
Mesoblast
Mesoblast Provides Topline Results From Phase 3 Trial Of Rexlemestrocel-L
December 2•
Mesoblast
FDA Grants Fast Track Designation For Remestemcel-L In The Treatment Of Acute Respiratory Distress Syndrome Due To Covid-19
December 2•
Mesoblast
Mesoblast Says U.S. FDA Granted Fast Track Designation For Remestemcel-L
November 19•
Mesoblast
Mesoblast Posts Qtrly Loss Attributable At US$24.5 Million
November 19•
Mesoblast
Mesoblast Enters Global Collaboration For Development, Manufacture And Commercialization Of Remestemcel-L
November 19•
Mesoblast
Novartis Secures Exclusive Rights For Potential Acute Respiratory Distress Syndrome Cell Therapy
October 29•
Mesoblast
Mesoblast Ltd Says Pursuing Parallel Approval Pathway For For Remestemcel-L For Covid-19 ARDS If Phase 3 Trial Is Positive
October 29•
Mesoblast
Mesoblast Updates On Qtrly Activities
October 13•
Mesoblast
Randomized Controlled Phase 3 Trial Of Remestemcel-L Surpasses 50% Enrollment
October 2•
Mesoblast
Mesoblast Updates On Bbiologics License Application For Graft Versus Host Disease
October 1•
Mesoblast
Mesoblast Seeks Trading Halt
September 4•
Mesoblast
Mesoblast Says DSMB Recommends Continuation Of Remestemcel-L Phase 3 Trial In Covid-19 Patients With Acute Respiratory Distress Syndrome
September 2•
Mesoblast
Mesoblast Ltd Receives Ethics Approval To Treat Covid-19 Patients In Australia
August 27•
Mesoblast
Mesoblast Posts FY Loss Attributable $77.9 Mln
August 14•
Mesoblast
Mesoblast Says Committee Of FDA Voted In Support Of Efficacy Of Remestemcel-L
July 30•
Mesoblast
Mesoblast - Independent Dsmb Set A Date For Early September To Complete First Interim Analysis Of Remestemcel-L Phase 3 Trial For Covid-19 Ards
July 6•
Mesoblast
Mesoblast Says Expanded Access Protocol Initiated For Compassionate Use Of Remestemcel-L In Children

Mesoblast News 2026

This page contains all current news, analysis and press releases for Mesoblast stock (MSB.AX, ISIN: AU000000MSB8). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Mesoblast.

Mesoblast Stock

Mesoblast Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future.